Capstone Therapeutics (NASDAQ:CAPS) Releases Earnings Results, Misses Estimates By $41.39 EPS

Capstone Therapeutics (NASDAQ:CAPS) issued its quarterly earnings data on Thursday. The company reported ($38.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.99 by ($41.39), FiscalAI reports. The business had revenue of $19.96 million for the quarter, compared to analysts’ expectations of $22.50 million. Capstone Therapeutics had a negative net margin of 36.51% and a negative return on equity of 144.43%.

Capstone Therapeutics Stock Down 11.4%

Capstone Therapeutics stock traded down $0.23 during trading hours on Thursday, reaching $1.79. The stock had a trading volume of 92,630 shares, compared to its average volume of 89,724. The company has a market cap of $1.65 million, a price-to-earnings ratio of -0.02 and a beta of -1.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.39. The business’s 50 day moving average price is $3.88 and its 200-day moving average price is $10.27. Capstone Therapeutics has a 52 week low of $1.78 and a 52 week high of $34.80.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Capstone Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, November 4th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury. The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.